Human Microbiome-based Drugs and Diagnostics: Global Markets

Report Code: BIO151B

Publish Date: May 2025

Publisher: BCC Publishing

Category: Cell Biology

Download Report OverviewTARIFF UPDATE

Limited Period Offer

CUSTOMIZE NOW

Explore Our Services

Already a member? Login to access this report free.

Report Highlights

The global market for human microbiome-based drugs and diagnostics is expected to grow from $393.4 million in 2025 to reach $1.2 billion by the end of 2030, at a compound annual growth rate (CAGR) of 25.6% from 2025 through 2030.

Report Includes

  • 55 data tables and 51 additional tables
  • Analyses of the trends in global markets for human microbiome-based drugs and diagnostics, with revenue data from 2022 to 2024, estimates for 2025, and projected CAGRs through 2030
  • Estimates of the size and revenue prospects for the global market, along with a market share analysis by type, drug route of administration, diagnostics product type, application, end user, and region
  • Facts and figures pertaining to market dynamics, opportunities and deterrents, technological advances, regulations, and the impacts of macroeconomic variables
  • Review of the prevalence of infectious diseases, metabolic disorders and chronic ailments
  • An assessment of current products, clinical trials and identification of new potential markets for novel products and assay development
  • Overview of the sustainability trends and ESG developments in the industry, with emphasis on the ESG practices followed by leading companies, their ESG ratings, and consumer attitudes
  • An analysis of the key patent grants and recently published patents
  • Analysis of the industry structure and value chain, and the competitive landscape, including companies’ market shares, strategic alliances, M&A activity, venture fundings and investment outlook
  • Profiles of the leading companies, including Ferring Pharmaceuticals, Nestlé Health Science, BiomeBank, Genetic Analysis AS, and Vedanta Biosciences Inc.

Report Scope

The report analyzes the global market for human microbiome-based drugs and diagnostics and market trends. It includes global revenues for the base year 2024, estimated data for 2025 and the compound annual growth rates (CAGRs) for forecast period of 2025 to 2030. The market is segmented by type, application, end user and region. The microbiome-based drug segment is further segmented by route of administration: oral or rectal. Microbiome-based diagnostics are segmented based on product type into instruments, and reagents and kits. End-user segments include hospitals and clinics, pharmaceutical companies and research institutes. Applications include metabolic, gastrointestinal (GI) and infectious diseases, cancer and others. The regions covered include North America, Europe, Asia-Pacific, South America and the Middle East and Africa (MEA). The report discusses emerging technologies and analyzes the competitive landscape, providing the ranking/market shares of leading companies in the market. It also includes a chapter on environmental, social and corporate governance (ESG) developments.

Human microbiome-based products that are intended for wellness or as dietary supplements are outside the scope of the report, as are nonstandardized fecal microbiota transplantation (FMT) procedures. Microbiome-based diagnostics include only products that claim to detect or screen for any disease or condition.

Report Synopsis

Report Metrics Details
Base year considered 2024
Forecast period considered 2025-2030
Base year market size $315.2 Million
Market size forecast $1.2 Billion
Growth rate CAGR of 25.6% from 2025 to 2030
Units considered $ Thousands
Segments covered By Type, Drug Route of Administration, Diagnostics Product Type, Application, End User, and Region
Regions covered North America, Europe, Asia-Pacific, South America and the Middle East and Africa (MEA)
Key Market Drivers
  • Growing evidence on microbiome-disease correlation.
  • Microbiome-based diagnostics for disease prevention and monitoring.
  • Drugs and diagnostics for skin and lung microbiomes.
  • Growing interest in direct-to-consumer (D2C) microbiome testing.
Companies studied
BIOMEBANKENTEROBIOTIX LTD.
ENTEROMEFERRING
GENETIC ANALYSISILLUMINA INC.
MICROBIOME INSIGHTSMICROBIOTICA
NESTLE HEALTH SCIENCEOXFORD NANOPORE TECHNOLOGIES PLC
PACBIOSFA THERAPEUTICS INC.
THERMO FISHER SCIENTIFIC INC.VEDANTA BIOSCIENCES INC.
Need pricing for multiple titles, a complete report bundle, or something specially curated to fit your budget? EXPLORE OFFERS

Frequently Asked Questions (FAQs)

The global human microbiome-based drugs and diagnostics market was valued at $315.2 million in 2024 and is expected to reach $1.2 billion by the end of 2030 at a CAGR of 25.6%.
The increasing clinical evidence on the impact of microbiomes on human health and the growing use of microbiome-based diagnostics for disease prevention and monitoring are driving the market growth.
The market is segmented based on type, application, end-user, and region. The market is segmented into microbiome drugs and microbiome diagnostics based on type. The microbiome drugs segment is further segmented based on the route of administration into oral and rectal. The microbiome-based diagnostics segment is further segmented based on product type into instruments and reagents & kits. Based on the end-user industry, the segments include hospitals and clinics, pharmaceutical companies, and research institutes. The market is segmented by application into metabolic diseases, cancer, gastrointestinal diseases, infectious diseases, and others. The report also focuses on regional segmentation of the market. The regions covered in this study include North America, Europe, Asia-Pacific, South America, and the Middle East and Africa (MEA), focusing on major countries in these regions.
Microbiome-based drugs will dominate the organ-on-a-chip market.
North America accounted for 62.1% share of the market in 2024.

Analyst Credentials

BCC Research Team possesses expertise and experience in life and physical science domains. They specialize in offering valuable business insights, including industry analysis, competitor intelligence, strategic and financial analysis, and opportunity assessment. The team has in-depth knowledge of various sectors, including healthcare, biotechnology, pharmaceuticals, IT, automation, advanced materials, and energy. They are proficient in qualitative and quantitative market intelligence providing clients with actionable insights. With a vast understanding of the competitive landscape, the team can support clients in making data-driven decisions to help them achieve a competitive edge in their respective markets.

Let us assist you! Our analysts are ready to tailor this report to your specific need. Talk to Our Analyst

Table of Contents

All reports provided in PDF format. For shared licensing options (5+ Users), please call a representative at (+1) 781-489-7301 or contact us at info@bccresearch.com
Title/Chapter NamePagesMember Price
Full Report: Human Microbiome-based Drugs and Diagnostics: Global Markets116Free
Chapter- 1: Executive Summary5Free
Chapter- 2: Market Overview14Free
Chapter- 3: Market Dynamics7Free
Chapter- 4: Regulatory Landscape3Free
Chapter- 5: Emerging Technologies3Free
Chapter- 6: Market Segmentation Analysis41Free
Chapter- 7: Competitive Intelligence5Free
Chapter- 8: Sustainability in the Human Microbiome-based Drugs and Diagnostics Industry: An ESG Perspective2Free
Chapter- 9: Appendix36Free
Published - May-2017| Analyst - Meghna Mehta| Code - BIO151A

Report Highlights

The global market for human microbiome-based drugs and diagnostics should reach a market size of nearly $9.9 billion by 2024.

Report Includes

  • An overview of the global markets for human microbiome-based drugs and diagnostics.
  • Analyses of global market trends, with estimates from 2017, and projections of compound annual growth rates (CAGRs) through 2024.
  • Coverage of areas and applications where these technologies are applicable, such as cancer, diabetes, allergic disorders, irritable bowel disorders, celiac disease, and other G.I. disorders.
  • An in-depth look at macro-level trends affecting this sector.
  • Market intelligence on the technologies and platforms currently being deployed to develop these drugs and diagnostics.
  • Specific emphasis on the products in development for various diseases, including the specific forecasts for these products by disease and geography.
  • A look at the current level of investments in the sector, intellectual property development, and future of this sector.

Related Reports

Global Microbiome Sequencing Market

Published - May 2025 | Publisher - BCC Publishing | Code - BIO183B

The global microbiome sequencing market is expected to grow from $1.5 billion in 2024 and is projected to reach $3.7 billion by the end of 2029, at a compound annual growth rate (CAGR) of 19.3% during the forecast period of 2024 to 2029.

Global DNA Sequencing: Research, Applied and Clinical Markets

Published - Dec 2024 | Publisher - BCC Publishing | Code - BIO045J

The global market for DNA sequencing is expected to grow from $14.8 billion in 2024 and is projected to reach $34.8 billion by the end of 2029, at a compound annual growth rate (CAGR) of 18.6% during the forecast period of 2024 to 2029.

Direct-to-Consumer Testing Industry: Global Markets

Published - Jun 2024 | Publisher - BCC Publishing | Code - HLC269B

The global market for direct-to-consumer (DTC) testing is estimated to increase from $1.6 billion in 2023 to reach $3.2 billion by 2029, at a compound annual growth rate (CAGR) of 12.5% from 2024 through 2029.

Microbial Products: Technologies, Applications and Global Markets

Published - Jun 2023 | Publisher - BCC Publishing | Code - BIO086E

The global market for microbes and microbial products is estimated to increase from $242.0 billion in 2022 to reach $346.3 billion by 2027, at a compound annual growth rate (CAGR) of 7.4% from 2022 through 2027.

Recent Reports

Human Microbiome-based Drugs and Diagnostics: Global Markets

Published - May 2025 | Publisher - BCC Publishing | Code - BIO151B

The global market for human microbiome-based drugs and diagnostics is expected to grow from $393.4 million in 2025 to reach $1.2 billion by the end of 2030, at a compound annual growth rate (CAGR) of 25.6% from 2025 through 2030.

Global Microbiome Sequencing Market

Published - May 2025 | Publisher - BCC Publishing | Code - BIO183B

The global microbiome sequencing market is expected to grow from $1.5 billion in 2024 and is projected to reach $3.7 billion by the end of 2029, at a compound annual growth rate (CAGR) of 19.3% during the forecast period of 2024 to 2029.

Proteomics: Technologies and Global Markets

Published - May 2025 | Publisher - BCC Publishing | Code - BIO034G

The global market for proteomic technologies was valued at $27.6 billion in 2024. It is projected to grow from $31.0 billion in 2025 to $57.2 billion by the end of 2030, at a compound annual growth rate (CAGR) of 13.0% from 2025 to 2030.

Biologic Therapeutic Drugs: Technologies and Global Markets

Published - May 2025 | Publisher - BCC Publishing | Code - BIO079F

The global market for biologic therapeutic drugs is estimated to increase from $499.2 billion in 2024 to reach $794.5 billion by 2029, at a compound annual growth rate (CAGR) of 9.7% from 2024 through 2029.

Global Markets and Manufacturing Technologies for Protein Drugs

Published - Apr 2025 | Publisher - BCC Publishing | Code - BIO021G

The global protein drugs market is expected to grow from $441.7 billion in 2024 and is projected to reach $655.7 billion by the end of 2029, at a compound annual growth rate (CAGR) of 8.2% during the forecast period of 2024 to 2029.

Top Trending Reports

Global Markets for Emerging Medical Device Technologies

Published - Mar 2025 | Publisher - BCC Publishing | Code - HLC191C

The global market for emerging medical devices is estimated to increase from $136.6 billion in 2024 to reach $223.9 billion by 2029, at a compound annual growth rate (CAGR) of 10.4% from 2024 through 2029.

Global Diabetic Care Devices Market

Published - Feb 2025 | Publisher - BCC Publishing | Code - MDS019B

The global market for diabetes monitoring devices is expected to grow from $16.6 billion in 2024 to $26.8 billion by the end of 2029, at a compound annual growth rate (CAGR) of 10.1% from 2024 through 2029.

2024 Medical Devices Research Review

Published - Mar 2025 | Publisher - BCC Publishing | Code - MDS060B

The medical device industry is a multi-billion-dollar industry whose outlook is supposed to rise in the coming years These devices treat and diagnose a multitude of patient conditions and work much better than drugs.

Global Lithium-ion Battery Market

Published - Mar 2025 | Publisher - BCC Publishing | Code - FCB067A

The global market for lithium-ion battery (LIB) is expected to grow from $117.8 billion in 2024 and is projected to reach $221.7 billion by the end of 2029, at a compound annual growth rate (CAGR) of 13.5% during the forecast period of 2024 to 2029.

Generative AI: Global Markets

Published - Jan 2025 | Publisher - BCC Publishing | Code - IFT308A

The global market for generative AI was valued at $15.4 billion in 2023. It is projected to grow from $20.8 billion in 2024 to $94.4 billion by 2029, at a compound annual growth rate (CAGR) of 35.3% from 2024 through 2029.

Become A Member

BCC Research offers a comprehensive library of reports, granting members unlimited access to data, insights, and market intelligence for informed business decisions, while actively supporting members in their evolving journeys and prioritizing high-quality, relevant topics based on continuous engagement with the research community.

Find Out More

Custom Consulting

BCC Research emphasizes the importance of organizations leveraging highly customized market insights aligned with specific strategic business objectives through direct engagement with primary sources and proprietary forecasting models for profitable decision-making in maximizing growth opportunities and minimizing risks.

Customize Now

Scorecard

The Venture Scorecard provides commercialization offices and decision makers with expert analysis, offering strategic insights crucial for aligning objectives with market realities at various stages of commercializing new products or evaluating investment opportunities, from opportunity assessment to growth planning.

Find Out More

Innovation Spotlight

Our industry experts offer strategic guidance to maximize the market potential of commercialized products, patents, and IP by providing insights into market trends, competitive dynamics, and effective positioning, using the Innovation Spotlight service for enhanced exposure to thought leaders and the wider community.

Find Out More
Human Microbiome-based Drugs and Diagnostics: Global Markets
Sample Report